Exelixis Inc Payments to Acquire Restricted Investments
Exelixis Inc (EXEL) reported Payments to Acquire Restricted Investments of $15.65 million for the 12-month period ending 2017-12-29, per its 10-K filed 2018-02-26.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireRestrictedInvestments · last filed 2018-02-26
- Exelixis Inc payments to acquire restricted investments for the quarter ending 2017-12-29 was $4.50M, a 0.00% change year-over-year.
- Exelixis Inc payments to acquire restricted investments for the quarter ending 2017-09-30 was $5.00M.
- Exelixis Inc payments to acquire restricted investments for the quarter ending 2017-06-30 was $2.65M, a 23.30% increase year-over-year.
- Exelixis Inc payments to acquire restricted investments for the quarter ending 2017-03-31 was $3.50M, a 74.85% increase year-over-year.
- Exelixis Inc payments to acquire restricted investments for fiscal 2017 was $15.65M, a 80.92% increase from fiscal 2016.
- Exelixis Inc payments to acquire restricted investments for fiscal 2016 was $8.65M.
- Exelixis Inc payments to acquire restricted investments for fiscal 2016 was $8.65M, a 53.10% increase from fiscal 2016.
- Exelixis Inc payments to acquire restricted investments for fiscal 2016 was $5.65M.
| Period end | Payments to Acquire Restricted Investments 3 month | Payments to Acquire Restricted Investments 6 month | Payments to Acquire Restricted Investments 9 month | Payments to Acquire Restricted Investments 12 month |
|---|---|---|---|---|
| 2017-12-29 | $4.50M derived: 10-K 12 month − 3 quarters · filed 2018-02-26 | $9.50M derived: sum of 2 quarters · filed 2018-02-26 | $12.15M derived: sum of 3 quarters · filed 2018-02-26 | $15.65M 10-K · filed 2018-02-26 |
| 2017-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $7.65M derived: sum of 2 quarters · filed 2017-11-01 | $11.15M 10-Q · filed 2017-11-01 | $15.65M derived: sum of 4 quarters · filed 2017-11-01 |
| 2017-06-30 | $2.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $6.15M 10-Q · filed 2017-08-02 | $10.65M derived: sum of 3 quarters · filed 2017-08-02 | $10.65M derived: sum of 4 quarters · filed 2017-11-01 |
| 2017-03-31 | $3.50M 10-Q · filed 2017-05-01 | $8.00M derived: sum of 2 quarters · filed 2017-05-01 | $8.00M derived: sum of 3 quarters · filed 2017-11-01 | $10.15M derived: sum of 4 quarters · filed 2017-11-01 |
| 2016-12-31 | $4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $4.50M derived: sum of 2 quarters · filed 2017-11-01 | $6.65M derived: sum of 3 quarters · filed 2017-11-01 | $8.65M 10-K · filed 2017-02-27 |
| 2016-12-30 | $8.65M 10-K · filed 2018-02-26 | |||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $2.15M derived: sum of 2 quarters · filed 2017-11-01 | $4.15M 10-Q · filed 2017-11-01 | $7.18M derived: sum of 4 quarters · filed 2017-11-01 |
| 2016-06-30 | $2.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $4.15M 10-Q · filed 2017-08-02 | $7.18M derived: sum of 3 quarters · filed 2017-08-02 | $5.62M derived: sum of 4 quarters · filed 2017-08-02 |
| 2016-03-31 | $2.00M 10-Q · filed 2017-05-01 | $5.04M derived: sum of 2 quarters · filed 2017-05-01 | $3.47M derived: sum of 3 quarters · filed 2017-05-01 | $4.97M derived: sum of 4 quarters · filed 2017-05-01 |
| 2016-01-01 | $5.65M 10-K · filed 2018-02-26 | |||
| 2015-12-31 | $3.03M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $1.47M derived: sum of 2 quarters · filed 2017-02-27 | $2.97M derived: sum of 3 quarters · filed 2017-02-27 | $5.65M 10-K · filed 2017-02-27 |
| 2015-09-30 | -$1.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$68.00K derived: sum of 2 quarters · filed 2016-11-03 | $2.62M 10-Q · filed 2016-11-03 | $2.58M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $4.18M 10-Q · filed 2016-08-03 | $4.14M derived: sum of 3 quarters · filed 2017-02-27 | $7.68M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-03-31 | $2.68M 10-Q · filed 2016-05-04 | $2.64M derived: sum of 2 quarters · filed 2017-02-27 | $6.18M derived: sum of 3 quarters · filed 2017-02-27 | $10.32M derived: sum of 4 quarters · filed 2017-02-27 |
| 2014-12-31 | -$41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $3.50M derived: sum of 2 quarters · filed 2017-02-27 | $7.64M derived: sum of 3 quarters · filed 2017-02-27 | $8.14M 10-K · filed 2017-02-27 |
| 2014-09-30 | $3.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $7.68M derived: sum of 2 quarters · filed 2015-11-10 | $8.18M 10-Q · filed 2015-11-10 | $10.48M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $4.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | $4.64M 10-Q · filed 2015-08-11 | $6.94M derived: sum of 3 quarters · filed 2016-02-29 | $6.94M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $504.00K 10-Q · filed 2015-04-30 | $2.80M derived: sum of 2 quarters · filed 2016-02-29 | $2.81M derived: sum of 3 quarters · filed 2016-02-29 | $6.08M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $2.30M derived: sum of 2 quarters · filed 2016-02-29 | $5.58M derived: sum of 3 quarters · filed 2016-02-29 | $6.08M 10-K · filed 2016-02-29 |
| 2013-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $3.28M derived: sum of 2 quarters · filed 2014-11-04 | $3.79M 10-Q · filed 2014-11-04 | $5.08M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-06-30 | $3.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $3.78M 10-Q · filed 2014-07-31 | $5.08M derived: sum of 3 quarters · filed 2015-03-02 | $45.40M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-03-31 | $504.00K 10-Q · filed 2014-05-01 | $1.80M derived: sum of 2 quarters · filed 2015-03-02 | $42.12M derived: sum of 3 quarters · filed 2015-03-02 | $41.48M derived: sum of 4 quarters · filed 2015-03-02 |
| 2012-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $41.62M derived: sum of 2 quarters · filed 2015-03-02 | $40.98M derived: sum of 3 quarters · filed 2015-03-02 | $41.48M 10-K · filed 2015-03-02 |
| 2012-09-30 | $40.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $39.68M derived: sum of 2 quarters · filed 2013-10-30 | $40.19M 10-Q · filed 2013-10-30 | |
| 2012-06-30 | -$636.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | -$132.00K 10-Q · filed 2013-08-06 | ||
| 2012-03-31 | $504.00K 10-Q · filed 2013-05-07 | |||
| 2011-12-31 | $5.90M 10-K · filed 2014-02-20 | |||
| 2010-12-31 | $8.10M 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |